Our findings gain novel insights into how PI3K inhibitors exert their activity by modulating the tumor-immune interaction, and provide a rationale for the concurrent targeting of PI3K and FASN inhibitor in breast cancer treatment. The gene discussed is FASN; the disease is breast carcinoma.